The Irritable bowel syndrome is a gastrointestinal disorder of gut
that may be acknowledged by the colon muscle contraction. It majorly distresses
the large intestine. In addition, it is linked with the malfunction of the
bowel, and majorly happens in geriatric populace. Diarrhea, constipation,
alteration & uneasiness in bowel function, bloating, and abdominal pain are
some of the mutual symptoms of the irritable bowel syndrome.
Endoscopy and blood test are customarily performed to perceive
this irritable bowel syndrome. Irritable bowel syndrome is categorized into
three forms such as IBS with diarrhea (IBS-D), IBS with constipation (IBS-C),
and mixed IBS. Handling of irritable bowel syndrome involves the proper
medicines, variation in diet, stress relief, and counseling. Medicines utilized
in the treatment of irritable bowel syndrome involve rifaximin, eluxadoline,
lubiprostone, linaclotide, and several others.
According to the report analysis, ‘Irritable Bowel Syndrome Treatment Market by Type (IBS
with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed IBS (IBS-M),
Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and
End User (Hospitals Pharmacies, Drug Stores & Retail Pharmacies, and Online
Pharmacies): Global Opportunity Analysis and Industry Forecast, 2019-2026’states
that in the irritable bowel syndrome treatment market there are innumerable
entities which presently working more proficiently for leading the fastest
market growth and registering the great value of market share around the globe
during the coming future while analyzing and studying the strategies of the
competitors, developing the specifications of the technologies, advancing the
profits and applications of such, employing the effective strategies of profit
making, spreading the awareness related to the irritable bowel syndrome
treatment, delivering the better consumer satisfaction, decreasing the
associated price and employing the young work force includes Abbott
Laboratories, Allergan plc, Ardelyx Inc., Astellas Pharma Inc., AstraZeneca
plc, GlaxoSmithKline Plc, Johnson & Johnson (McNeil Consumer Healthcare),
Novartis AG, Sebela Pharmaceuticals Inc., Takeda Pharmaceutical Company Ltd and
numerous others.
Although, the irritable bowel syndrome treatment market was worth at USD 1,071 million in 2018, and is estimated to reach at USD 2,012 million by 2026, dominating a CAGR of 8.2% from 2019 to 2026. Whereas, effective increase in the prevalence of gastrointestinal diseases and disorders such as modification of the bowel habit, abdominal pain, implementation of sedentary lifestyle, augment in level of stress, and unhealthy diet are the foremost factors that influence the growth of the irritable bowel syndrome treatment market.
According to the International Foundation for Gastrointestinal
Disorders (IFFGD), it was projected that the irritable bowel syndrome affects nearly
25-45 million in the U.S. in 2016. Moreover, company advancing the products
with symptom precise application and subsequent launches, augment in the
geriatric population, and speedy growth in the awareness programs for irritable
bowel syndrome treatment are other aspects that contribute toward the growth of
the market. Furthermore, effective increase in prevalence of irritable bowel
syndrome in female is projected to further boost the growth of worldwide
irritable bowel treatment market throughout the forecast period. Therefore, in
the near years, it is anticipated that the market of irritable bowel syndrome
treatment will increase around the globe more actively over the forthcoming
future.
For More Information, refer to
below link:-
Global
Irritable Bowel Syndrome Treatment Market
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
No comments:
Post a Comment